Bani Ahluwalia1, Maria K Magnusson2, Stefan Isaksson3, Fredrik Larsson4, Lena Öhman5. 1. Department of Microbiology and Immunology, Sahlgrenska Academy at University of Gothenburg, Box 435, 405 30 Gothenburg, Sweden; Calmino Group AB, Sahlgrenska Science Park, Medicinaregatan 8A, 413 46 Gothenburg, Sweden. Electronic address: bani.ahluwalia@calmino.com. 2. Department of Microbiology and Immunology, Sahlgrenska Academy at University of Gothenburg, Box 435, 405 30 Gothenburg, Sweden; Department of Internal Medicine and Clinical Nutrition, Sahlgrenska Academy at University of Gothenburg, 413 45 Gothenburg, Sweden. Electronic address: maria.magnusson@microbio.gu.se. 3. Department of Microbiology and Immunology, Sahlgrenska Academy at University of Gothenburg, Box 435, 405 30 Gothenburg, Sweden; Department of Internal Medicine and Clinical Nutrition, Sahlgrenska Academy at University of Gothenburg, 413 45 Gothenburg, Sweden. Electronic address: stefan.isaksson@microbio.gu.se. 4. Department of Internal Medicine and Clinical Nutrition, Sahlgrenska Academy at University of Gothenburg, 413 45 Gothenburg, Sweden. Electronic address: fredrik.larsson@calmino.com. 5. Department of Microbiology and Immunology, Sahlgrenska Academy at University of Gothenburg, Box 435, 405 30 Gothenburg, Sweden; Department of Internal Medicine and Clinical Nutrition, Sahlgrenska Academy at University of Gothenburg, 413 45 Gothenburg, Sweden. Electronic address: lena.ohman@microbio.gu.se.
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE: Aloe barbadensis Mill. (Aloe vera) is a widely used medicinal plant well reputed for its diverse therapeutic applications. It has been used for thousands of years in folk medicine to treat various conditions and the Aloe vera gel has been reported to possess anti-inflammatory as well as immunostimulatory and immunomodulatory properties. However, the mode of action is still unclear. AIM OF THE STUDY: The aim of this study was determine the effects of two well-defined A. barbadensis Mill. extracts AVH200® and AVE200 on human blood T cells in vitro. MATERIALS AND METHODS: Peripheral blood mononuclear cells (PBMC) from healthy donors were stimulated polyclonally in the presence or absence of AVH200® and AVE200. The T cell phenotype was investigated by flow cytometry, cell proliferation was determined by CFSE dye and thymidine assay, respectively and cytokine secretion was determined by MSD® Multi-Spot Assay system and ELISA. RESULTS: The presence of AVH200® resulted in a reduced expression of CD25 among CD3(+) T cells and suppression of T cell proliferation in a dose dependent manner. Furthermore, AVH200® reduced the expression of CD28 on CD3(+) T cells. AVH200® also reduced the secretion of IL-2, IFN-γ and IL-17A in PBMC cultures. The AVH200® dose dependent reduction in T cell activation and proliferation recorded in the cell cultures was not due to apoptosis or cell death. Additionally, AVH200® was found to be more effective as compared to AVE200 in reducing T cell activation and proliferation. CONCLUSION: AVH200® has the potential to reduce the activation, proliferation and cytokine secretion of healthy human blood T cells. Our study suggests that AVH200® has a suppressive effect on human blood T cells in vitro.
ETHNOPHARMACOLOGICAL RELEVANCE: Aloe barbadensis Mill. (Aloe vera) is a widely used medicinal plant well reputed for its diverse therapeutic applications. It has been used for thousands of years in folk medicine to treat various conditions and the Aloe vera gel has been reported to possess anti-inflammatory as well as immunostimulatory and immunomodulatory properties. However, the mode of action is still unclear. AIM OF THE STUDY: The aim of this study was determine the effects of two well-defined A. barbadensis Mill. extracts AVH200® and AVE200 on human blood T cells in vitro. MATERIALS AND METHODS: Peripheral blood mononuclear cells (PBMC) from healthy donors were stimulated polyclonally in the presence or absence of AVH200® and AVE200. The T cell phenotype was investigated by flow cytometry, cell proliferation was determined by CFSE dye and thymidine assay, respectively and cytokine secretion was determined by MSD® Multi-Spot Assay system and ELISA. RESULTS: The presence of AVH200® resulted in a reduced expression of CD25 among CD3(+) T cells and suppression of T cell proliferation in a dose dependent manner. Furthermore, AVH200® reduced the expression of CD28 on CD3(+) T cells. AVH200® also reduced the secretion of IL-2, IFN-γ and IL-17A in PBMC cultures. The AVH200® dose dependent reduction in T cell activation and proliferation recorded in the cell cultures was not due to apoptosis or cell death. Additionally, AVH200® was found to be more effective as compared to AVE200 in reducing T cell activation and proliferation. CONCLUSION: AVH200® has the potential to reduce the activation, proliferation and cytokine secretion of healthy human blood T cells. Our study suggests that AVH200® has a suppressive effect on human blood T cells in vitro.
Authors: Bani Ahluwalia; Maria K Magnusson; Lena Böhn; Stine Störsrud; Fredrik Larsson; Lena Öhman; Magnus Simrén Journal: Therap Adv Gastroenterol Date: 2021-10-08 Impact factor: 4.409
Authors: Bani Ahluwalia; Maria K Magnusson; Fredrik Larsson; Otto Savolainen; Alastair B Ross; Lena Öhman Journal: Molecules Date: 2022-10-06 Impact factor: 4.927